Kaomi ma aneʻi e hōʻike i kāu mau hae ma kēia ʻaoʻao a uku wale no ka holomua

Nuhou Uea

Nā hualoaʻa maikaʻi hou no ka mālama ʻana i ka maʻi ʻehaʻeha

i kakauia ma hoʻoponopono

Ua hoʻolaha ʻo ACELYRIN, INC., Affibody AB, a me Inmagene Biopharmaceuticals Co., Ltd., i kēia lā he 16-week, honua, Phase 2 hoʻokolohua lapaʻau o izokibep i 135 mau mea maʻi me ka psoriatic arthritis (PsA) i hālāwai me kāna kumu hope o ACR50. Ua loaʻa pū ʻo Izokibep i nā helu hope lua, me ka pane PASI, ka hoʻomaikaʻi ʻana i ka enthesitis LEEDs, a me ka hoʻomaikaʻi ʻana i ke ola o ka maikaʻi o ka PsA-specific maikaʻi o ke ola kino, ka nīnau nīnau Psoriatic Impact of Disease (PsAID).   

Ua loiloi ka ho'āʻo hoʻokolohua lapaʻau ʻelua-makapō ʻelua, placebo-controlled, Phase 2 i ka palekana a me ka pono o ka izokibep dosed 80 mg i kēlā me kēia pule ʻelua (Q2W) a i ʻole 40 mg Q2W, versus placebo Q2W, i nā poʻe maʻi me ka PsA ikaika. ʻO ka hopena mua o ACR50 a me ka hope hope o nā pane PASI ua hālāwai a aia ma luna o ka laulā o nā pane, ke hoʻohālikelike ʻia i nā mea i hōʻike ʻia no nā lāʻau lapaʻau ʻē aʻe i ʻae ʻia a i ʻole i ka hoʻomohala ʻana no PsA. ʻO ka māhele o nā poʻe maʻi me ka hoʻonā ʻana o ka enthesitis ʻike ʻia he ʻokoʻa. Ua hoʻokō ʻia kahi hoʻomaikaʻi koʻikoʻi i ka maikaʻi o ke ola maʻi me ke ana hopena i hōʻike ʻia e ka mea maʻi, PsAID. ʻAʻohe pilikia palekana hou i ʻike ʻia.

"ʻO ka ʻikepili maikaʻi i hana ʻia i kēia hoʻokolohua Phase 2 e kākoʻo i kā mākou hypothesis ʻo ke kiʻekiʻe kiʻekiʻe a me ka liʻiliʻi o ka molecular liʻiliʻi o ka izokibep e hopena i ka hiki ke loaʻa i nā hōʻike nui aʻe, no laila, ʻoi aku ka maikaʻi. ʻO ka hoʻonui ʻia ʻana o ka lāʻau lapaʻau i loko o nā ʻiʻo entheseal vascularized maikaʻi ʻole e kūlike me nā hōʻemi ʻeha nui i ʻike ʻia me ka mālama ʻana izokibep, "wahi a Paul Peloso, MD, ka luna lapaʻau nui (CMO) o ACELYRIN.

"Hoʻopili ʻia ka ʻeha entheseal koena me ka maʻi koʻikoʻi a me ka maikaʻi ʻole o ke ola. He mea hauʻoli ka ʻike ʻana i ka hoʻonā maikaʻi ʻana o ka enthesitis a me ka maikaʻi o ke ola o nā mea maʻi, "wahi āna.

"He maʻi ʻeha ʻeha a hoʻohaʻahaʻa ʻo Psoriatic arthritis o nā hui peripheral, ʻili, a me nā kui, a hiki ke hoʻopilikia i ka iwi kuamoʻo. Ua hauʻoli mākou i kēia ho'āʻo Phase 2 e hōʻike ana i ka hiki o ka izokibep e hāʻawi i ka maikaʻi ʻokoʻa ma kēia wahi o ka pono ʻole i hoʻomau ʻia," wahi a Prof. Nikolai Brun, MD, PhD, CMO o Affibody. "ʻO ka mea nui, ke hoʻomau nei ka manawa e ʻimi ai i nā hōʻike kiʻekiʻe e hoʻopaʻa i ka pane a hāʻawi mau i ka izokibep ma ke ʻano he hoʻokahi SC injections."

Ua ʻōlelo ʻo Shao-Lee Lin, MD, PhD, co-founder a me CEO o ACELYRIN, "Ke hōʻike nei kēia mau ʻikepili i ko mākou hilinaʻi i ka hoʻolālā i hoʻolaha mua ʻia no ka loiloi piha ʻana i ka hiki o ka inhibition IL-17A no ka hiki ke hoʻololi i nā kūlana maʻi."

"He hopena maikaʻi ka ʻikepili PsA P2 no ka axial spondyloarthritis (AxSpA) a me psoriasis (PsO), i hāʻawi ʻia i ka hopena i ka enthesitis a me nā pane PASI. E aʻo ʻia ka dosing kiʻekiʻe (160mg QW) a me Q2W dosing o izokibep i kahi haʻawina pivotal PsA P2b/3 ma ke ʻano he hana hou i ka holomua o ka papahana, "wahi āna.

Ua ʻōlelo ʻo David Bejker, Luna Hoʻokele o Affibody, "He mea koʻikoʻi kēia mau hopena noiʻi i ka hōʻike ʻana i ka manawa kūpono e hana ai i nā pūhui papa maikaʻi loa e pili ana i ka ʻenehana Affibody®."

E hōʻike ʻia nā kikoʻī o ka ʻikepili hoʻāʻo PsA Phase 2 e ka hōʻike podium ma ka European Alliance of Associations for Rheumatology (EULAR) Congress ma Copenhagen ma Iune 3, 2022, ma 11:05AM CET.

Paʻa ʻo ACELYRIN i nā kuleana honua i ka izokibep koe wale nō ka hoʻomohala ʻana a me nā kuleana kūʻai aku e Inmagene ma nā ʻāina ʻĀsia i koho ʻia, me Kina, Hong Kong, South Korea, a me Taiwan, a me Iapana. Paʻa ʻo Affibody i nā kuleana ʻoihana ma nā ʻāina Nordic.

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...